NRAS and metastatic colorectal cancer: BRAF and KRAS mutations have been reported to occur in ∼10% and 44% of patients with metastatic colorectal cancer, which is similar to frequency (KRAS: 46%; BRAF: 11.2%; NRAS: 3%) observed in our sample cohort (28).